{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:50:40Z","timestamp":1761540640719,"version":"build-2065373602"},"reference-count":42,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":2451,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:p>\n                    <jats:bold>Study Objective.<\/jats:bold>\n                    To evaluate the differential effect on coagulation and fibrinolysis parameters of combination therapy with glimepiride\u2010metformin and with rosiglitazone\u2010metformin beyond their effect on glucose metabolism in patients with type 2 diabetes and metabolic syndrome.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design.<\/jats:bold>\n                    Multicenter, double\u2010blind, randomized, controlled trial.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Setting.<\/jats:bold>\n                    Two university\u2010affiliated medical centers in Italy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients.<\/jats:bold>\n                    Ninety\u2010five patients with type 2 diabetes for at least 6 months without glycemic control by diet and oral hypoglycemic agents to their maximum tolerated dosage and who also had metabolic syndrome.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Intervention.<\/jats:bold>\n                    All 95 patients received metformin 1500 mg\/day In a randomized manner, 47 patients received glimepiride 2 mg\/day and 48 patients received rosiglitazone 4 mg\/day.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Measurements and Main Results.<\/jats:bold>\n                    Body mass index (BMI), glycemic control, and coagulation and fibrinolysis parameters were evaluated at 3, 6, 9, and 12 months of treatment. Compared with baseline values, significant decreases in BMI, fasting plasma glucose, postprandial plasma glucose, and hemoglobin A\n                    <jats:sub>1c<\/jats:sub>\n                    were observed at 12 months in both the glimepiride and rosiglitazone groups (p&lt;0.05 and p&lt;0.01, respectively). Decreases in fasting plasma insulin and postprandial plasma insulin were observed at 12 months (p&lt;0.05 and p&lt;0.01, respectively) compared with baseline values in the rosiglitazone group. Furthermore, improvement in the Homeostasis Model Assessment index was observed only at 9 and 12 months (p&lt;0.05 and p&lt;0.01, respectively) compared with baseline in the rosiglitazone group. Significant improvement in plasminogen activator inhibitor (PAI)\u20101 was present in the rosiglitazone group after 9 months (p&lt;0.05), and significant PAI\u20101 improvement was observed in the glimepiride and rosiglitazone groups after 12 months (p&lt;0.05 and p&lt;0.01, respectively).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.<\/jats:bold>\n                    The rosiglitazone\u2010metformin combination significantly improved the long\u2010term control of all insulin resistance\u2013related parameters compared with the glimepiride\u2010metformin combination. However, both combinations were associated with a slight but statistically significant improvement in PAI\u20101 value, related to a similar reduction in insulin resistance.\n                  <\/jats:p>","DOI":"10.1592\/phco.25.5.637.63587","type":"journal-article","created":{"date-parts":[[2005,6,14]],"date-time":"2005-06-14T04:43:46Z","timestamp":1118724226000},"page":"637-645","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Antithrombotic Effects of Rosiglitazone\u2010Metformin versus Glimepiride\u2010Metformin Combination Therapy in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome"],"prefix":"10.1002","volume":"25","author":[{"given":"Giuseppe","family":"Derosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio V.","family":"Gaddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario N.","family":"Piccinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardina","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibilla","family":"Salvadeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Peros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morena","family":"Ghelfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arrigo F. G.","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00088-3"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00611-X"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.10.1182"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-003-0072-3"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-002-0050-2"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02555-9"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127002762491271"},{"issue":"4","key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1262-3636(03)72787-6","article-title":"Beneficial effects of metformin on haemostasis and vascular function in man","volume":"29","author":"Grant P.","year":"2003","journal-title":"Diabetes Metab"},{"key":"e_1_2_1_11_2","first-page":"S21","article-title":"Screening for diabetes [position statement]","volume":"24","author":"American Diabetes Association.","year":"2001","journal-title":"Diabetes Care"},{"volume-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity, 3\u20135 June 1997","year":"1998","author":"World Health Organization.","key":"e_1_2_1_12_2"},{"key":"e_1_2_1_13_2","first-page":"151","article-title":"1999 World Health Organization\u2013International Society of Hypertension guidelines for the management of hypertension. Guidelines subcommittee","volume":"17","author":"World Health Organization\u2013International Society of Hypertension.","year":"1999","journal-title":"J Hypertens"},{"key":"e_1_2_1_14_2","first-page":"S44","article-title":"Nutrition recommendations and principles for people with diabetes mellitus [position statement]","volume":"24","author":"American Diabetes Association.","year":"2001","journal-title":"Diabetes Care"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.635569"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.1999.00166.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01225569"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/1047-2797(92)90092-5"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000205234"},{"key":"e_1_2_1_21_2","first-page":"1","article-title":"Preanalytical aspects of coagulation testing","volume":"80","author":"Narayanan S.","year":"1995","journal-title":"Haematologica"},{"volume-title":"Statistical principles in experimental design, 2nd ed","year":"1971","author":"Winer BJ.","key":"e_1_2_1_22_2"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1155\/2004\/797458"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00279.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.9.2057"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-978677"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802778"},{"key":"e_1_2_1_28_2","first-page":"673","article-title":"Contribution of PAI\u20131 in cardiovascular pathology","volume":"97","author":"Alessi MC","year":"2004","journal-title":"Arch Mal Coeur"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.6.1582"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00254-4"},{"journal-title":"Acta Diabetol","article-title":"Long\u2010term effect of thiazolidinediones on nonconventional cardiovascular risk factors: a randomized, double\u2010blind clinical trial on patients affected by metabolic syndrome","author":"Derosa G","key":"e_1_2_1_31_2"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00338-7"},{"issue":"6","key":"e_1_2_1_33_2","first-page":"5","article-title":"Is metformin more than an oral hypoglycaemic agent?","volume":"29","author":"Vague P.","year":"2003","journal-title":"Diabet Metab"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.12.2244"},{"key":"e_1_2_1_35_2","first-page":"854","article-title":"Effect of intensive blood\u2010glucose control with metformin on complications in overweight patients with type 2 diabetes","volume":"253","author":"UK Prospective Diabetes Study (UKPDS) Group.","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012512"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2.4.699"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.12.7.1179"},{"key":"e_1_2_1_39_2","first-page":"406","article-title":"Thiazolidinediones in diabetes: current status and future outlook","volume":"4","author":"Camp HS.","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2002.00663.x"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2003.00258.x"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80090-5"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2003.00276.x"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.25.5.637.63587","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.25.5.637.63587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:01:10Z","timestamp":1761069670000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.25.5.637.63587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1592\/phco.25.5.637.63587"],"URL":"https:\/\/doi.org\/10.1592\/phco.25.5.637.63587","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}